Sev­en years af­ter li­cens­ing BTK in­hibitor from Bio­gen, be­lea­guered pen­ny­s­tock biotech part­ner con­cedes de­feat

A BTK in­hibitor Bio­gen punt­ed out of its pipeline years ago has flopped its first clin­i­cal test.

Day­ton Mis­feldt

Sune­sis Phar­ma said it would not be tak­ing ve­cabru­ti­nib in­to the Phase II por­tion of its Phase Ib/II tri­al af­ter re­view­ing ini­tial da­ta that sug­gest lim­it­ed ef­fi­ca­cy even at the high­est dose. The tri­al had en­rolled adult pa­tients with re­lapsed/re­frac­to­ry chron­ic lym­pho­cyt­ic leukemia (CLL) and oth­er B-cell ma­lig­nan­cies. The safe­ty pro­file was “ex­cel­lent”; it just didn’t seem to have much of an ef­fect.

Day­ton Mis­feldt, the Bay City Cap­i­tal VC who’s been in­ter­im CEO for more than two years, summed it up this way:

One par­tial re­mis­sion was ob­served af­ter 11 treat­ment cy­cles in a CLL pa­tient treat­ed in Co­hort 5 (300 mg BID) and a num­ber of pa­tients treat­ed across the dose range ex­plored (25 mg to 500 mg BID) saw sta­ble dis­ease; how­ev­er, no oth­er re­mis­sions have been ob­served.

The Phase Ib pro­gram will con­tin­ue while Sune­sis ex­ecs de­cide on the drug’s fate. Shares of the South San Fran­cis­co com­pa­ny on the Nas­daq — a pen­ny­s­tock — plum­met­ed 43.68% to $0.35 pre-mar­ket.

For now, Sune­sis will shift its fo­cus and re­sources to a PDK-1 in­hibitor dubbed SNS-510 — a process that should be fa­mil­iar to the com­pa­ny by now.

When it went pub­lic in 2005, the lead prod­uct can­di­date was SNS-595 (vosarox­in), a cell-cy­cle in­hibitor lat­er po­si­tioned for leukemia. Reg­u­la­tors spurned their Phase III da­ta and Sune­sis end­ed up out-li­cens­ing it to De­n­o­vo Bio­phar­ma, which spe­cial­izes in find­ing ap­plic­a­ble sub­groups for drugs that have com­plet­ed tri­als with “un­sat­is­fac­to­ry ef­fi­ca­cy.” Not much came out of the sec­ond project to de­vel­op an Au­ro­ra ki­nase in­hibitor, ei­ther.

The cur­rent pipeline of two con­sists en­tire­ly of as­sets orig­i­nat­ing from a col­lab­o­ra­tion with Bio­gen, who was al­so an eq­ui­ty hold­er. Aside from ve­cabru­ti­nib, a non-co­va­lent in­hibitor of BTK that promised to help Im­bru­vi­ca-re­sis­tant pa­tients, SNS-510 tar­gets PI3K-de­pen­dent and PIP3-in­de­pen­dent path­ways.

With Take­da on board as a part­ner, an IND is in the works for the end of 2020. The cash re­serves should be enough to get them there — but like­ly not that much be­yond.

Forge Bi­o­log­ics’ cGMP Com­pli­ant and Com­mer­cial­ly Vi­able Be­spoke Affin­i­ty Chro­matog­ra­phy Plat­form

Forge Biologics has developed a bespoke affinity chromatography platform approach that factors in unique vector combinations to streamline development timelines and assist our clients in efficiently entering the clinic. By leveraging our experience with natural and novel serotypes and transgene conformations, we are able to accelerate affinity chromatography development by nearly 3-fold. Many downstream purification models are serotype-dependent, demanding unique and time-consuming development strategies for each AAV gene therapy product1. With the increasing demand to propel AAV gene therapies to market, platform purification methods that support commercial-scale manufacturing of high-quality vectors with excellent safety and efficacy profiles are essential.

Cy­to­ki­net­ics’ ALS drug fails PhI­II, leav­ing the biotech with a sin­gle late-stage prospect

Cytokinetics’ candidate for the muscle disease amyotrophic lateral sclerosis, or ALS, failed a Phase III trial, the Bay Area biotech announced Friday morning.

At a second interim analysis of the trial, an independent review committee recommended that Cytokinetics discontinue its COURAGE-ALS trial for reldesemtiv, as it “found no evidence of effect” compared to placebo on the primary or key secondary endpoints.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

CHMP gives thumbs-up for We­govy use in ado­les­cents, along with nine new drug rec­om­men­da­tions

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended nine drugs for approval this week while also giving thumbs up for six expanded indications, including Novo Nordisk’s approved obesity medication Wegovy for younger people. Wegovy is already approved as an obesity treatment in the EU for adults, and the new indication would allow prescriptions for adolescents aged 12 and older.

Mathai Mammen, FogPharma's next CEO

Math­ai Mam­men hands in J&J's R&D keys to lead Greg Ver­dine’s Fog­Phar­ma 

In the early 1990s, Mathai Mammen was a teaching assistant in Greg Verdine’s Science B46 course at Harvard. In June, the former R&D head at Johnson & Johnson will succeed Verdine as CEO, president and chair of FogPharma, the same month the seven-year-old biotech kickstarts its first clinical trial.

After leading R&D at one of the largest drugmakers in the world, taking the company through more than half a dozen drug approvals in the past few years, not to mention a Covid-19 vaccine race, Mammen departed J&J last month and will take the helm of a Cambridge, MA biotech attempting to go after what Verdine calls the “true emperor of all oncogenes” — beta-catenin.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

Austin biotech Mol­e­c­u­lar Tem­plates lays off more than 100 staffers as pipeline nar­rows

Molecular Templates is ridding itself of a Phase I HER2 asset and fine-tuning its pipeline to focus on three programs and a preclinical Bristol Myers Squibb collaboration. With the narrowed scope on its so-called engineered toxin bodies, the Austin, TX biotech is laying off about half of its staff.

That’s a little more than 100 employees, per an SEC filing. Molecular’s layoffs, approved by its board Wednesday, add to the dozens of pullbacks in the industry in the first three months of 2023.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

Aptinyx eval­u­ates fu­ture of the com­pa­ny fol­low­ing two failed tri­als, 60% lay­offs

This year has been tough for Aptinyx — two failed trials, a 60% cut in its workforce, and now the company has brought on a firm to help evaluate the future of the company.

The press release noted it’s working with the firm Ladenburg Thalmann as its financial advisor to assist in exploring and evaluating “strategic alternatives” — a process that a growing group of struggling biotechs has embarked on, sometimes ending in a merger, asset sale or wind-down.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

Sar­to­rius to ac­quire French man­u­fac­tur­er for $2.6B+ in cell and gene ther­a­py play

The German life science group Sartorius will be picking up French contract manufacturer Polyplus for the price of €2.4 billion, or $2.6 billion.

On Friday, Sartorius announced the acquisition through its French subgroup, Sartorius Stedim Biotech, which will be acquiring Polyplus from private investors ARCHIMED and WP GG Holdings IV. Polyplus has 270 employees and produces materials and components that go into making viral vectors that are used in cell and gene therapies. This includes DNA/RNA reagents as well as plasmid DNA. Polyplus has locations in France, Belgium, China and the US.

Green­Light re­ceives buy­out of­fer; Apol­lomics com­pletes SPAC merg­er

RNA biotech GreenLight Biosciences has been handed an offer for potential acquisition.

GreenLight said in a release that it has received a non-binding “indication of interest” from Fall Line Endurance Fund to acquire GreenLight’s capital stock for $0.60 per share in cash. The release said any potential agreement between the two parties would depend on certain conditions.

Through a special committee, the biotech will evaluate the offer but added there’s no certainty a deal will go forward. GreenLight will also not make any more announcements until a deal comes through or “otherwise determines” a statement is necessary.

TScan Therapeutics' departing CEO David Southwell and CSO/COO Gavin MacBeath

TCR up­start an­nounces CEO ex­it, with CSO now act­ing re­place­ment

A public T cell biotech’s chief executive has decided to leave the company.

TScan Therapeutics said Friday morning that CEO David Southwell stepped down earlier this week, leaving both his chief executive and board member roles. Filling in is Gavin MacBeath, the company’s CSO and COO. He became the acting CEO on Tuesday, and will continue to remain CSO and COO, TScan’s announcement read.